InflaRx NV
NASDAQ:IFRX
InflaRx NV
Research & Development
InflaRx NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
InflaRx NV
NASDAQ:IFRX
|
Research & Development
-€27.4m
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Research & Development
-€2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Research & Development
-€141.4m
|
CAGR 3-Years
44%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Research & Development
-€176.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Research & Development
-€56.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Formycon AG
XETRA:FYB
|
Research & Development
-€15.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
InflaRx NV
Glance View
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. The company is headquartered in Jena, Thueringen and currently employs 59 full-time employees. The company went IPO on 2017-11-16. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
See Also
What is InflaRx NV's Research & Development?
Research & Development
-27.4m
EUR
Based on the financial report for Sep 30, 2025, InflaRx NV's Research & Development amounts to -27.4m EUR.
What is InflaRx NV's Research & Development growth rate?
Research & Development CAGR 5Y
2%
Over the last year, the Research & Development growth was 25%. The average annual Research & Development growth rates for InflaRx NV have been 11% over the past three years , 2% over the past five years .
